Nephrogen is a biotechnology company based in New York City, NY[2][4] that develops curative genetic medicines for kidney and pancreatic diseases[1][3]. Founded as a Stanford biotech spin-out[7], the company went through Y Combinator's Summer 2020 batch[5] and operates with a team size of 5[6]. Nephrogen's platform combines artificial intelligence and high-throughput screening to engineer gene delivery vehicles for reaching the kidney and pancreas[7]. The company has received non-dilutive funding from seven major pharmaceutical companies, including Merck KGaA, Novartis, and Bristol Myers Squibb[7].
About
- Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.[7]
Something wrong or missing? Send a correction. Fixed within 24 hours.